David Pierce Mysona

David Pierce Mysona

Auto-generated profile, based on publicly available information

David Pierce Mysona

Department of Gynecology Oncology, Medical University of South Carolina, Charleston, SC, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2019 in BMC Cancer
Verified
Journal Article
Open access
PDF file
EGEmily Gobin
Emily Gobin
KBKayla Bagwell
Kayla Bagwell
JWJohn Wagner
John Wagner
DMDavid Mysona
David Mysona
SSSharmila Sandirasegarane
Sharmila Sandirasegarane
JSJin-Xiong She
Jin-Xiong She
By understanding Matrix Metalloprotease (MMP) dysregulation from a pan-cancer perspective, this study sheds light on the diagnostic potentials of MMPs across multiple neoplasms. MMPs are intriguing genes related to cancer disease progression, functional promotion of angiogenesis, invasion, metastasis, and avoidance of immune surveillance. Many studies have noted these genes are frequently upregulated in cancer. However, expression patterns of all MMPs and their diagnostic and prognostic potential have not been investigated in a pan-cancer perspective. The Cancer Genome Atlas (TCGA) data were used to evaluate diagnostic and prognostic potential of 24 MMPs in fifteen different cancer types. Gene expression measured by RNA-seq was analyzed by differential expression, hierarchical clustering, and ROC analysis for individual genes and in combination. MMP1, MMP9, MMP10, MMP11, and MMP13 were almost universally upregulated across all cancers, with significant (p < 0.05) fold change (FC > 2) in ten of fifteen cancers. MMP3, MMP7, MMP12 and MMP14) are significantly up-regulated in at least 10 cancer types. Interestingly, MMP2, MMP7, MMP23B, MMP27 and MMP28) are significantly down-regulated in seven to nine cancer types. Multiple MMPs possess AUC’s > 0.9 in more than one cancer. However, survival analyses suggest that the prognostic value of MMPs is limited to clear cell renal carcinoma. Most MMPs have consistently increased gene expression across cancers, while several MMPs have consistently decreased expression in several cancer types. Many MMPs have diagnostic value individually or in combination, while the prognostic value of MMPs is restricted to one subtype of kidney cancer.


24 April 2024 in Cancers
Verified
Journal Article
Open access
PDF file
CWChaston Weaver
Chaston Weaver
ANAlisha Nam
Alisha Nam
CSCaitlin Settle
Caitlin Settle
MOMadelyn Overton
Madelyn Overton
MGMaya Giddens
Maya Giddens
SPSharad Purohit
Sharad Purohit
In 2020, the World Health Organization (WHO) reported 604,000 new diagnoses of cervical cancer (CC) worldwide, and over 300,000 CC-related fatalities. The vast majority of CC cases are caused by persistent human papillomavirus (HPV) infections. HPV-related CC incidence and mortality rates have declined worldwide because of increased HPV vaccination and CC screening with the Papanicolaou test (PAP test). Despite these significant improvements, developing countries face difficulty implementing these programs, while developed nations are challenged with identifying HPV-independent cases. Molecular and proteomic information obtained from blood or tumor samples have a strong potential to provide information on malignancy progression and response to therapy in CC. There is a large amount of published biomarker data related to CC available but the extensive validation required by the FDA approval for clinical use is lacking. The ability of researchers to use the big data obtained from clinical studies and to draw meaningful relationships from these data are two obstacles that must be overcome for implementation into clinical practice. We report on identified multimarker panels of serum proteomic studies in CC for the past 5 years, the potential for modern computational biology efforts, and the utilization of nationwide biobanks to bridge the gap between multivariate protein signature development and the prediction of clinically relevant CC patient outcomes.

27 November 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
DMDavid P. Mysona
David P. Mysona
SPSharad Purohit
Sharad Purohit
KRKatherine P. Richardson
Katherine P. Richardson
JSJessa Suhner
Jessa Suhner
BBBogna Brzezinska
Bogna Brzezinska
SGSharad Ghamande
Sharad Ghamande
In ovarian cancer, there is no current method to accurately predict recurrence after a complete response to chemotherapy. Here, we develop a machine learning risk score using serum proteomics for the prediction of early recurrence of ovarian cancer after initial treatment. The developed risk score was validated in an independent cohort with serum collected prospectively during the remission period. In the discovery cohort, patients scored as low-risk had a median time to recurrence (TTR) that was not reached at 10 years compared to 10.5 months (HR 4.66, p < 0.001) in high-risk patients. In the validation cohort, low-risk patients had a median TTR which was not reached compared to 4.7 months in high-risk patients (HR 4.67, p = 0.009). In advanced-stage patients with a CA125 < 10, low-risk patients had a median TTR of 68 months compared to 6 months in high-risk patients (HR 2.91, p = 0.02). The developed risk score was capable of distinguishing the duration of remission in ovarian cancer patients. This score may help guide maintenance therapy and develop innovative treatments in patients at risk at high-risk of recurrence.

5 November 2020 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
DMDavid Pierce Mysona
David Pierce Mysona
SGSharad Ghamande
Sharad Ghamande
JSJin-Xiong She
Jin-Xiong She
LTLynn Tran
Lynn Tran
PTPaul Tran
Paul Tran
PGPaola A. Gehrig
Paola A. Gehrig

20 May 2016 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
DMDavid Mysona
David Mysona
APAdam Pyrzak
Adam Pyrzak
JAJennifer Allen
Jennifer Allen
SBShan Bai
Shan Bai
ASAshok Sharma
Ashok Sharma
SGSharad A. Ghamande
Sharad A. Ghamande
E17005 Background: Cervical cancer is the second most common cancer of women worldwide. In this prospective study, we attempted to identify a set of serum biomarkers, which could identify patients who have invasive cervical cancer and monitor disease status (progression of disease (PD), remission (RM)). Biomarker selection focused on the matrix metalloproteinase (MMP) family and growth factors. Methods: In this IRB approved prospective study, luminex bead array was used to measure serum protein concentrations of 19 selected proteins in cervical cancer patients (CC) (n=23) compared to women with precancerous lesions (CIN2-3) (n=20), and patients with normal cervical cytology (n=20). Cervical cancer (adenocarcinoma and squamous carcinoma) patients had blood samples drawn within 30 days of diagnosis and repeat blood samples taken on follow up after completing therapy. Results were correlated to clinical data and outcomes. MMP7 expression was confirmed by immunohistochemistry (IHC). IHC scoring was done blindly by two pathologists independently. Results: Six proteins (CA153, OPG, CEA, IGFBP7, IGFBP4, and MMP-7) had significantly different levels in CC patients compared to controls and CIN (p < 0.05). MMP-7 had a sensitivity of 92% at 95% specificity. IHC revealed significant staining of MMP7 below the epithelial basement membrane of CC samples when compared to CINs and controls P<0.05. There was no difference in staining intensity between CINs, controls, and CC patients. MMP7 has significantly altered expression when comparing RM and PD (P<0.05). It also was an indicator of progression free survival (HR:4.5, P<0.05) and an indicator of overall survival at PD (P value = 0.04, HR= 7.5). Conclusions: MMP7 serum concentration is significantly altered when comparing CC patients to controls and CINs. This may be due to the overwhelming expression of MMP7 below the basement membrane in invasive CC. Further studies warrant investigating MMP7’s role in CC.